title: [Evaluation of prophylactic hepatic arterial infusion chemotherapy after hepatectomy for metastases from colorectal cancer].
abstract: The significance of continuous hepatic arterial infusion (HAI) chemotherapy of 5-FU to prevent recurrence in the remnant liver following curative hepatectomy for colorectal metastases was analyzed in the prospective randomized study. Patients of HAI chemotherapy group received 6 weeks of 5-FU 500 mg/day. The one- and two-year overall survival rates of nine patients with HAI therapy were 87.5% and 87.5%, respectively, while the rates of ten cases without the regional chemotherapy were 100% and 66.7%, respectively, indicating no obvious difference. On the other hand, the disease-free survival rates of HAI Group were higher than those of control group. The disease-free survival rates of the former were 75.0% at one-year and 75.0% at two-year, and the rates of the latter were 47.6% and 47.6%, respectively. No serious complications such as severe liver dysfunction, sclerotic cholangitis or hepatic necrosis were observed. Although the follow-up period was not enough long to accurately evaluate the efficacy, local prophylactic chemotherapy by continuous infusion of 5-FU could be a promising method as an adjuvant chemotherapy after hepatic resection for colorectal metastases.
authors.affiliation: Dept. of Surgery, Osaka National Hospital.
authors.forename: T
authors.initials: T
authors.lastname: Tono
authors.forename: N
authors.initials: N
authors.lastname: Kikkawa
authors.forename: Y
authors.initials: Y
authors.lastname: Tamaki
authors.forename: T
authors.initials: T
authors.lastname: Yagyu
authors.forename: H
authors.initials: H
authors.lastname: Mishima
authors.forename: T
authors.initials: T
authors.lastname: Morita
authors.forename: I
authors.initials: I
authors.lastname: Takemasa
authors.forename: K
authors.initials: K
authors.lastname: Fukuda
authors.forename: E
authors.initials: E
authors.lastname: Shin
authors.forename: K
authors.initials: K
authors.lastname: Kobayashi
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000473:pathology*; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006498:Hepatectomy; D006499:Hepatic Artery; D006801:Humans; D015918:Infusion Pumps, Implantable; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000401:mortality / Q000517:prevention & control* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011446:Prospective Studies
chemical_list: D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil